SuperworthDexCom profit margin DXCM
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 20.1%
- Operating margin, 12 months
- 22.9%
- Net margin on a year earlier
- +6.8 pts
- Peer median
- 13.4%
Over the twelve months to Jun 30, 2026, DexCom kept 20.1% of its revenue as net profit, with an operating margin of 22.9% and a gross margin of 62.5%.
Five years earlier its net margin was 25.9%.
The median for 9 medical device stocks of a similar size is 13.4%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 17.9% | 19.6% | 60.1% |
| FY2024 | 14.3% | 14.9% | 60.5% |
| FY2023 | 14.9% | 16.5% | 63.2% |
| FY2022 | 11.7% | 13.4% | 64.7% |
| FY2021 | 8.9% | 10.9% | 68.6% |
| FY2020 | 25.6% | 15.5% | 66.4% |
| FY2019 | 6.8% | 9.6% | 63.1% |
| FY2018 | −12.3% | −18.1% | 64.4% |
| FY2017 | −7.0% | −5.9% | 68.5% |
| FY2016 | −11.4% | −11.1% | 66.0% |
| FY2015 | −14.3% | −14.2% | 69.3% |
| FY2014 | −8.6% | −8.3% | 68.0% |
| FY2013 | −18.6% | −18.1% | 62.6% |
| FY2012 | −54.6% | −55.8% | 46.6% |
| FY2011 | −58.6% | −58.8% | 47.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 20.1% | +6.8 pts | 22.9% | |
| Q1 FY26 | 19.3% | +6.4 pts | 21.4% | |
| Q4 FY25 | 17.9% | +3.7 pts | 19.6% | |
| Q3 FY25 | 16.0% | −1.3 pts | 17.2% | |
| Q2 FY25 | 13.3% | −3.7 pts | 16.0% | |
| Q1 FY25 | 12.9% | −3.9 pts | 15.3% | |
| Q4 FY24 | 14.3% | −0.7 pts | 14.9% | |
| Q3 FY24 | 17.2% | +6.1 pts | 15.9% | |
| Q2 FY24 | 16.9% | +5.8 pts | 17.3% | |
| Q1 FY24 | 16.8% | +7.1 pts | 17.1% | |
| Q4 FY23 | 14.9% | +3.2 pts | 16.5% | |
| Q3 FY23 | 11.1% | +2.3 pts | 14.9% |
Against its peers
Companies in Medical - Devices nearest DexCom's size, closest first, today.
| Company | Profit margin |
|---|---|
| DXCMDexCom | 20.1% |
| GEHCGE HealthCare Technologies | 9.3% |
| ZBHZimmer Biomet | 9.5% |
| EWEdwards Lifesciences | 15.4% |
| BSXBoston Scientific | 17.5% |
| SYKStryker | 14.4% |
| MDTMedtronic | 13.9% |
| ABTAbbott Laboratories | n/m |
| LIVNLivaNova | 12.8% |
| ITGRInteger | 7.0% |
| Peer median | 13.4% |
Where DexCom ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on DexCom
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.